Vimarsana
Biggest News Aggregation in the World

Matthew Schrag News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Matthew Schrag. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Matthew Schrag Today - Breaking & Trending Today

Star USC scientist faces scrutiny — retracted papers and a paused drug trial - Vimarsana News

Star USC scientist faces scrutiny — retracted papers and a paused drug trial

A group of whistle-blowers submitted a report to the NIH that questioned the integrity of a celebrated neuroscientist's research and the safety of an experimental stroke treatment his company was developing.

Star USC scientist faces scrutiny — retracted papers and a paused drug trial - Vimarsana News

Star USC scientist faces scrutiny — retracted papers and a paused drug trial

A group of whistle-blowers submitted a report to the NIH that questioned the integrity of a celebrated neuroscientist's research and the safety of an experimental stroke treatment his company was developing.

Star USC scientist faces scrutiny — retracted papers and a paused drug trial - Vimarsana News

Star USC scientist faces scrutiny — retracted papers and a paused drug trial

A group of whistle-blowers submitted a report to the NIH that questioned the integrity of a celebrated neuroscientist's research and the safety of an experimental stroke treatment his company was developing.

USC scientist faces scrutiny — retracted papers, paused drug trial - Vimarsana News

USC scientist faces scrutiny — retracted papers, paused drug trial

USC's Berislav Zlokovic has faced questions about the integrity of his research. Since a whistleblower report last year, several papers have been retracted and a drug trial has been paused.

Alzheimer's Drug Trial Results Questioned After 'Damning' FDA Inspection Report - Cassava Sciences (NASDAQ:SAVA) - Vimarsana News

Alzheimer's Drug Trial Results Questioned After 'Damning' FDA Inspection Report - Cassava Sciences (NASDAQ:SAVA)

The credibility of the clinical trial results for an experimental Alzheimer's drug has been called into question following a critical inspection report by the Food and Drug Administration.